Advanced heart failure (AHF) represents 1 to 10% of the overall heart failure (HF) spectrum, with prevalence increasing due to the improvement of survival provided by guideline directed medical therapies (GDMT) [1]. Prognosis of AHF remains poor, with a 1-year mortality ranging from 25% to 75% [2,3]. In this setting, intravenous inotropic support represents an important option as bridge to advanced heart failure therapies (heart transplantation (HT) or mechanical circulatory support (MCS)) or as palliative therapy [1,4–7].
